Loading menu…

Erlotinib Induced Fatal Interstitial Lung Disease: An Underreported Toxicity

§ Rutgers Robert Wood Johnson Medical School

Send Message

To: Author

Erlotinib Induced Fatal Interstitial Lung Disease: An Underreported Toxicity

Article Fingerprint

ReserarchID

DISEASES2IWWV

Erlotinib Induced Fatal Interstitial Lung Disease: An Underreported Toxicity Banner

Key Research Insights

Synthesized scholarly intelligence & interactive research assistant
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
Reading Preferences
Font Size
Line Spacing
Background
This converted HTML version may contain rendering inconsistencies. Please refer to the PDF for the authoritative version, or click here to provide feedback.

Abstract

Lung cancer is the leading cause of cancer-related mortality around the world, with 85% of cases identified as non-small-cell lung cancer (NSCLC). Adenocarcinoma is the most common histologic subtype in the US and accounts for more than 50% of all NSCLC. Activating mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase are found in approximately 15% of NSCLC adenocarcinoma in the US (and up to 62% in Asia) and is more common in nonsmokers. The presence of such a mutation is associated with a more favorable prognosis and predicts for sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. Treatment is well tolerated, with mild common adverse side effects of skin rash and diarrhea. However, increased experience with the use of these drugs has led to reports of rare serious adverse effects such as interstitial lung disease.

References

17 Cites in Article
  1. 1. A Jemal,R Seigel,J Xu,E Ward (2010). Cancer statistics. CA Cancer J Clini, 60(5), 277-300.
  2. 2. M Scaltriti,J Baselga (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 12(18), 5268-5272.
  3. 3. R Herbst,J Heymach,S Lippman (2008). Lung cancer. NEJM, 358, 1367-1380.
  4. 4. Martin Cohen,John Johnson,Yeh-Fong Chen,Rajeshwari Sridhara,Richard Pazdur (2005). FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets. The Oncologist, 10(7), 461-466.
  5. 5. Martin Cohen,Grant Williams,Rajeshwari Sridhara,Gang Chen,W Mcguinn,David Morse,Sophia Abraham,Atiqur Rahman,Chenyi Liang,Richard Lostritto,Amy Baird,Richard Pazdur (2004). United States Food and Drug Administration Drug Approval Summary. Clinical Cancer Research, 10(4), 1212-1218.
  6. 6. Wei-Xiang Qi,Li-Na Tang,Ai-Na He,Yang Yao,Zan Shen (2013). Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: A meta-analysis of 22 phase III randomized controlled trials. Respiratory Medicine, 107(8), 1280-1283.
  7. 7. H Nasrallah,G Bar-Sela,N Haim (2012). Fatal interstitial lung disease associated with gemcitabine and ertolinib therapy for lung cancer. Med Oncol, 29(1), 212-214.
  8. 8. Kelly Tammaro,Patricia Baldwin,Ante Lundberg (2005). Interstitial lung disease following erlotinib (Tarceva®) in a patient who previously tolerated gefitinib (Iressa®). Journal of Oncology Pharmacy Practice, 11(3), 127-130.
  9. 9. Katsuyuki Hotta,Katsuyuki Kiura,Nagio Takigawa,Hiroshige Yoshioka,Shingo Harita,Shoichi Kuyama,Toshiro Yonei,Keiichi Fujiwara,Tadashi Maeda,Keisuke Aoe,Hiroshi Ueoka,Haruhito Kamei,Shigeki Umemura,Tomonori Moritaka,Yoshihiko Segawa,Haruyuki Kawai,Akihiro Bessho,Katsuya Kato,Masahiro Tabata,Mitsune Tanimoto (2010). Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience. Journal of Thoracic Oncology, 5(2), 179-184.
  10. 10. Shinsuke Aida,Seiichi Tamai,Susumu Sekiguchi,Nobuyoshi Shimizu (1994). Distribution of Epidermal Growth Factor and Epidermal Growth Factor Receptor in Human Lung: Immunohistochemical and Immunoelectron-Microscopic Studies. Respiration, 61(3), 161-166.
  11. 11. Vincent Liu,Dorothy White,Maureen Zakowski,William Travis,Mark Kris,Michelle Ginsberg,Vincent Miller,Christopher Azzoli (2007). Pulmonary Toxicity Associated With Erlotinib. Chest, 132(3), 1042-1044.
  12. 12. M Peerzada,T Spiro,H Daw (2011). Pulmonary Toxicities of Tyrosine Kinase Inhibitors. Clin Advan Hem and Onc, 9(11), 824-836.
  13. 13. Chou Cl,H Ko,C Wang,C Yu,H Kuo,C Huand (2010). Erlotinibassociated near fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. Chang Guand Med J, 33(1), 100-105.
  14. 14. A Katzenstein,Askin Katzenstein (2006). s Surgical Pathology of Nonneoplastic Lung Disease. s Surgical Pathology of Nonneoplastic Lung Disease, 32-33.
  15. 15. Shaohua Ren,Yuan Li,Weiwen Li,Zhongwei Zhao,Chunxian Jin,Dengke Zhang (2012). Fatal Asymmetric Interstitial Lung Disease after Erlotinib for Lung Cancer. Respiration, 84(5), 431-435.
  16. 16. Hideomi Yamashita,W Takahashi,A Haga,K Nakagawa (2014). Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World Journal of Radiology, 6(9), 708.
  17. 17. Hongqing Zhuang,Zhiyong Yuan,Jun Wang,Qinsong Pang,Lujun Zhao,Ping Wang,Hailing Hou (2014). Preliminary analysis of the risk factors for radiation pneumonitis in patients with non- small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy. OncoTargets and Therapy, 807.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Ramy Sedhom, Elan Gorshein, Jane Date Hon, Judith Amorosa, Serena Wong. 2016. "Erlotinib Induced Fatal Interstitial Lung Disease: An Underreported Toxicity". Global Journal of Medical Research - F: Diseases GJMR-F Volume 16 (GJMR Volume 16 Issue 22 (F5)).

More Citation Formats

Download Citation

Issue Cover
GJMR Volume 16 Issue 22 (F5)
Pg. 23-28
Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-F Classification NLMC Code: WF600
Version of record
v1.2

Issue date
July 4, 2016

Language
English
Order Article Reprint
Experience in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 1.5K
Total Downloads: 125
All Trends

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Erlotinib Induced Fatal Interstitial Lung Disease: An Underreported Toxicity

Ramy Sedhom
Ramy Sedhom

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X